Merck will continue to investigate opportunities to further reduce the cost of our antiretrovirals for people living in resource-limited settings, including through partnering with external manufacturers and suppliers to achieve incremental efficiencies.
In emerging markets, we will continue to investigate new business models to drive our revenue growth while also ensuring access.
We remain committed to continued R&D investment in new treatments for HIV.
We will continue to engage in creative partnerships that address the full range of factors affecting access to medicines and the impact of HIV/AIDS in resource-constrained settings.
